Rein Therapeutics (RNTX) Competitors $1.36 +0.11 (+8.33%) As of 03:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock RNTX vs. COYA, EQ, ADAG, BMEA, ANEB, MGNX, SAVA, TCRX, ANRO, and SPROShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Coya Therapeutics (COYA), Equillium (EQ), Adagene (ADAG), Biomea Fusion (BMEA), Anebulo Pharmaceuticals (ANEB), MacroGenics (MGNX), Cassava Sciences (SAVA), TScan Therapeutics (TCRX), Alto Neuroscience (ANRO), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Its Competitors Coya Therapeutics Equillium Adagene Biomea Fusion Anebulo Pharmaceuticals MacroGenics Cassava Sciences TScan Therapeutics Alto Neuroscience Spero Therapeutics Rein Therapeutics (NASDAQ:RNTX) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Is RNTX or COYA more profitable? Coya Therapeutics' return on equity of -61.05% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -141.11% -33.83% Coya Therapeutics N/A -61.05%-53.61% Do analysts prefer RNTX or COYA? Coya Therapeutics has a consensus price target of $16.50, indicating a potential upside of 158.62%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor RNTX or COYA? In the previous week, Coya Therapeutics had 4 more articles in the media than Rein Therapeutics. MarketBeat recorded 5 mentions for Coya Therapeutics and 1 mentions for Rein Therapeutics. Coya Therapeutics' average media sentiment score of 0.69 beat Rein Therapeutics' score of 0.59 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in RNTX or COYA? 90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by insiders. Comparatively, 12.0% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, RNTX or COYA? Rein Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Which has stronger valuation and earnings, RNTX or COYA? Coya Therapeutics has higher revenue and earnings than Rein Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$62.88M-$2.69-0.51Coya Therapeutics$3.55M30.07-$14.88M-$1.24-5.15 SummaryCoya Therapeutics beats Rein Therapeutics on 10 of the 14 factors compared between the two stocks. Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.81M$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-0.5121.0383.0126.65Price / SalesN/A379.60503.06163.66Price / Cash3.1143.5325.7028.92Price / Book10.508.1210.796.52Net Income-$62.88M-$53.35M$3.29B$266.21M7 Day Performance20.80%0.06%0.03%-0.75%1 Month Performance21.88%7.09%7.09%3.84%1 Year PerformanceN/A11.93%50.11%24.40% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein TherapeuticsN/A$1.37+8.3%N/AN/A$31.81MN/A-0.519News CoverageHigh Trading VolumeCOYACoya Therapeutics2.6882 of 5 stars$6.86+4.1%$16.50+140.5%+9.3%$114.73M$3.55M-5.536News CoverageAnalyst ForecastEQEquillium0.512 of 5 stars$1.90+21.8%$1.00-47.4%+92.6%$113.06M$41.10M-3.3940News CoverageShort Interest ↑ADAGAdagene3.0696 of 5 stars$2.39+4.8%$7.00+192.9%-27.6%$112.59M$100K0.00260News CoverageShort Interest ↓BMEABiomea Fusion3.4199 of 5 stars$1.83+1.9%$16.80+818.0%-73.7%$108.90MN/A-0.6050ANEBAnebulo Pharmaceuticals1.9656 of 5 stars$2.60+5.7%$5.50+111.5%+35.9%$106.82MN/A-10.004Gap DownMGNXMacroGenics4.0426 of 5 stars$1.69+17.4%$3.60+113.0%-41.8%$106.82M$149.96M-2.96430Gap UpHigh Trading VolumeSAVACassava Sciences2.4017 of 5 stars$2.20+2.3%$2.00-9.1%-92.1%$106.28MN/A-0.8630Positive NewsTCRXTScan Therapeutics2.5885 of 5 stars$1.87+7.5%$7.80+317.1%-65.3%$105.83M$2.82M-1.72100News CoverageANROAlto Neuroscience3.0178 of 5 stars$3.91+8.8%$8.50+117.6%-72.6%$105.60MN/A0.00N/ASPROSpero Therapeutics4.3544 of 5 stars$1.87+0.5%$5.00+167.4%+55.2%$105.23M$47.98M-1.91150News CoverageShort Interest ↓ Related Companies and Tools Related Companies COYA Competitors EQ Competitors ADAG Competitors BMEA Competitors ANEB Competitors MGNX Competitors SAVA Competitors TCRX Competitors ANRO Competitors SPRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
